{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Precursor+Cell+Lymphoblastic+Leukemia-Lymphoma&page=54",
    "query": {
      "condition": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 1728,
    "total_pages": 173,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Precursor+Cell+Lymphoblastic+Leukemia-Lymphoma&page=55&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Precursor+Cell+Lymphoblastic+Leukemia-Lymphoma&page=53&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:03:20.413Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01188798",
      "title": "Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelocytic Leukemia",
        "Chronic Myelocytic Leukemia",
        "Hodgkin's Disease",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pentostatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "18 Months to 21 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-09",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2013-03-21",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188798"
    },
    {
      "nct_id": "NCT02906371",
      "title": "Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoblastic Leukemia, Acute, Childhood"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "CART 19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "1 Year to 24 Years"
      },
      "enrollment_count": 80,
      "start_date": "2016-08",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02906371"
    },
    {
      "nct_id": "NCT02043587",
      "title": "Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia",
        "Adult Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "DNR",
          "type": "DRUG"
        },
        {
          "name": "VCR",
          "type": "DRUG"
        },
        {
          "name": "PEG-asp",
          "type": "DRUG"
        },
        {
          "name": "CTX",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Liposomal AraC",
          "type": "DRUG"
        },
        {
          "name": "MTX",
          "type": "DRUG"
        },
        {
          "name": "LCV",
          "type": "DRUG"
        },
        {
          "name": "AraC",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 31,
      "start_date": "2014-01",
      "completion_date": "2022-04-14",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 4,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 1 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02043587"
    },
    {
      "nct_id": "NCT02879695",
      "title": "Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent Mixed Phenotype Acute Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Blinatumomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2017-10-25",
      "completion_date": "2027-07-18",
      "has_results": true,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 7,
      "location_summary": "New Haven, Connecticut • Lexington, Kentucky • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02879695"
    },
    {
      "nct_id": "NCT00089271",
      "title": "17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Stage III Adult Burkitt Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Mixed Cell Lymphoma",
        "Stage III Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult T-cell Leukemia/Lymphoma",
        "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage III Marginal Zone Lymphoma",
        "Stage III Mycosis Fungoides/Sezary Syndrome",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult T-cell Leukemia/Lymphoma",
        "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Mycosis Fungoides/Sezary Syndrome",
        "Stage IV Small Lymphocytic Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "alvespimycin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2004-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-25",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089271"
    },
    {
      "nct_id": "NCT05848687",
      "title": "TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "PEG asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        },
        {
          "name": "Ziftomenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tanja Andrea Gruber",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "Up to 1 Year"
      },
      "enrollment_count": 90,
      "start_date": "2023-11-03",
      "completion_date": "2033-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05848687"
    },
    {
      "nct_id": "NCT04556084",
      "title": "Blinatumomab Bridging Therapy for BALL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Relapsed B-cell Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Burke",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 2,
      "start_date": "2021-01-01",
      "completion_date": "2022-10-01",
      "has_results": true,
      "last_update_posted_date": "2025-05-13",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04556084"
    },
    {
      "nct_id": "NCT01660607",
      "title": "Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myeloid Leukemia, Chronic",
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndromes (MDS)",
        "Lymphoma, Non-Hodgkin",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Myeloproliferative Syndrome",
        "Acute Myeloid Leukemia",
        "Acute Leukemia",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "CD34+ Hematopoietic Progenitor Cells (HSPC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Regulatory T-Cells (Treg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conventional T-Cells (Tcon)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Myeloablative Conditioning Regimen",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "73 Years",
        "sex": "ALL",
        "summary": "13 Years to 73 Years"
      },
      "enrollment_count": 68,
      "start_date": "2012-02-09",
      "completion_date": "2023-12-20",
      "has_results": true,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01660607"
    },
    {
      "nct_id": "NCT01129193",
      "title": "AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Post-transplant Lymphoproliferative Disorder",
        "Prolymphocytic Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Multiple Myeloma",
        "Stage III Adult Burkitt Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Mixed Cell Lymphoma",
        "Stage III Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult Immunoblastic Large Cell Lymphoma",
        "Stage III Adult Lymphoblastic Lymphoma",
        "Stage III Adult T-cell Leukemia/Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage III Marginal Zone Lymphoma",
        "Stage III Multiple Myeloma",
        "Stage III Mycosis Fungoides/Sezary Syndrome",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Immunoblastic Large Cell Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Adult T-cell Leukemia/Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Mycosis Fungoides/Sezary Syndrome",
        "Stage IV Small Lymphocytic Lymphoma",
        "Testicular Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Pharmacodynamic Studies",
          "type": "OTHER"
        },
        {
          "name": "Fatigue Inventory",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic studies",
          "type": "OTHER"
        },
        {
          "name": "AR-42",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Amir Mortazavi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2010-05-04",
      "completion_date": "2017-01-07",
      "has_results": false,
      "last_update_posted_date": "2018-06-04",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129193"
    },
    {
      "nct_id": "NCT02349178",
      "title": "Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Acute Lymphoblastic",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "Up to 39 Years"
      },
      "enrollment_count": 6,
      "start_date": "2014-12-08",
      "completion_date": "2017-03-16",
      "has_results": true,
      "last_update_posted_date": "2020-03-09",
      "last_synced_at": "2026-11-19T05:03:20.413Z",
      "location_count": 4,
      "location_summary": "Columbus, Ohio • Madison, Wisconsin • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349178"
    }
  ]
}